LLY vs VKTX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Viking Therapeutics maintains its strong 10x growth potential, with no material changes since the last analysis warranting a significant score adjustment. The company's lead asset, VK2735, a dual GLP-1/GIP agonist, continues to be a compelling candidate in the lucrative metabolic disorder market. Positive Phase 2 data for both injectable and oral formulations positions it as a potential best-in-cl...